Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1Dermatologic 1

Conditions

Thyroid Cancer, Papillary 2Adenocarcinoma, Follicular 2Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Melanoma 1Leukoplakia, Oral 1Head and Neck Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 4spartalizumab 2tislelizumab 1obinutuzumab 1naptumomab estafenatox 1durvalumab 1Topotecan 1Rosiglitazone 1Nivolumab 1Metformin 1Gemcitabine 1Cisplatin 1Carboplatin 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma Of Esophagus × Rosiglitazone × Head & Neck × Clear all
NCT04114136 2026-04-24

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

University of Pittsburgh

Phase 2 Recruiting
72 enrolled
DermatologicGastrointestinalHead & Neck

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hepatocellular, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡